Sarepta Therapeutics (SRPT) Change in Accured Expenses (2010 - 2026)

Sarepta Therapeutics' Change in Accured Expenses history runs 17 years deep, the most recent figure standing at -$3.4 million for Q1 2026.

• In Q1 2026, Change in Accured Expenses fell 110.88% year-over-year to -$3.4 million; the TTM figure through Mar 2026 stood at $69.2 million (down 70.58% YoY), while the FY2025 annual figure was $104.3 million, down 5.77% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at -$3.4 million, down from $249.6 million in the prior quarter.
• The five-year high for Change in Accured Expenses was $249.6 million in Q4 2025, with the low at -$103.2 million in Q3 2025.
• The 5-year median for Change in Accured Expenses is $1.7 million (2024), against an average of $18.2 million.
• The sharpest annual moves came in 2024 and 2025: Change in Accured Expenses surged 396.97% in 2024, then slumped 6223.03% in 2025.
• Sarepta Therapeutics' Change in Accured Expenses stood at $12.9 million in 2022, then soared by 374.36% to $61.1 million in 2023, then soared by 103.34% to $124.2 million in 2024, then jumped by 100.96% to $249.6 million in 2025, then tumbled by 101.38% to -$3.4 million in 2026.
• Business Quant data shows SRPT's Change in Accured Expenses at -$3.4 million in Q1 2026, $249.6 million in Q4 2025, and -$103.2 million in Q3 2025.